Literature DB >> 23886741

Assessment of angiographic vascularity of meningiomas with dynamic susceptibility contrast-enhanced perfusion-weighted imaging and diffusion tensor imaging.

C H Toh1, K-C Wei, C N Chang, Y-W Peng, S-H Ng, H-F Wong, C-P Lin.   

Abstract

BACKGROUND AND
PURPOSE: The roles of DTI and dynamic susceptibility contrast-enhanced-PWI in predicting the angiographic vascularity of meningiomas have not been studied. We aimed to investigate if these 2 techniques could reflect the angiographic vascularity of meningiomas.
MATERIALS AND METHODS: Thirty-two consecutive patients with meningiomas who had preoperative dynamic susceptibility contrast-enhanced-PWI, DTI, and conventional angiography were retrospectively included. The correlations between angiographic vascularity of meningiomas, classified with a 4-point grading scale, and the clinical or imaging variables-age and sex of patient, as well as size, CBV, fractional anisotropy, and ADC of meningiomas-were analyzed. The meningiomas were dichotomized into high-vascularity and low-vascularity groups. The differences in clinical and imaging variables between the 2 groups were compared. Receiver operating characteristic curve analysis was used to determine the diagnostic performance of these variables.
RESULTS: In meningiomas, angiographic vascularity correlated positively with CBV but negatively with fractional anisotropy. High-vascularity meningiomas demonstrated significantly higher CBV but lower fractional anisotropy as compared with low-vascularity meningiomas. In differentiating between the 2 groups, the area under the curve values were 0.991 for CBV and 0.934 for fractional anisotropy on receiver operating characteristic curve analysis.
CONCLUSIONS: CBV and fractional anisotropy correlate well with angiographic vascularity of meningiomas. They may differentiate between low-vascularity and high-vascularity meningiomas.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23886741      PMCID: PMC7965772          DOI: 10.3174/ajnr.A3651

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  30 in total

1.  Correlation between dynamic contrast-enhanced perfusion MRI relative cerebral blood volume and vascular endothelial growth factor expression in meningiomas.

Authors:  Daniel T Ginat; Rajiv Mangla; Gabrielle Yeaney; Pamela W Schaefer; Henry Wang
Journal:  Acad Radiol       Date:  2012-05-15       Impact factor: 3.173

2.  Biexponential analysis of diffusion-tensor imaging of the brain in patients with cirrhosis before and after liver transplantation.

Authors:  L Chavarria; J Alonso; R García-Martínez; F X Aymerich; E Huerga; C Jacas; V Vargas; J Cordoba; A Rovira
Journal:  AJNR Am J Neuroradiol       Date:  2011-06-23       Impact factor: 3.825

3.  MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders.

Authors:  D Le Bihan; E Breton; D Lallemand; P Grenier; E Cabanis; M Laval-Jeantet
Journal:  Radiology       Date:  1986-11       Impact factor: 11.105

4.  Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging.

Authors:  Ramon F Barajas; Joanna J Phillips; Rupa Parvataneni; Annette Molinaro; Emma Essock-Burns; Gabriela Bourne; Andrew T Parsa; Manish K Aghi; Michael W McDermott; Mitchel S Berger; Soonmee Cha; Susan M Chang; Sarah J Nelson
Journal:  Neuro Oncol       Date:  2012-06-18       Impact factor: 12.300

5.  Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not.

Authors:  J L Boxerman; K M Schmainda; R M Weisskoff
Journal:  AJNR Am J Neuroradiol       Date:  2006-04       Impact factor: 3.825

6.  Embolization of meningiomas: comparison of safety between calibrated microspheres and polyvinyl-alcohol particles as embolic agents.

Authors:  M Sluzewski; W J van Rooij; P N Lohle; G N Beute; J P Peluso
Journal:  AJNR Am J Neuroradiol       Date:  2012-10-18       Impact factor: 3.825

7.  Differentiation between classic and atypical meningiomas with use of diffusion tensor imaging.

Authors:  C-H Toh; M Castillo; A M-C Wong; K-C Wei; H-F Wong; S-H Ng; Y-L Wan
Journal:  AJNR Am J Neuroradiol       Date:  2008-06-26       Impact factor: 3.825

8.  Differentiation of primary central nervous system lymphoma and high-grade glioma with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging.

Authors:  Weihua Liao; Yunhai Liu; Xiaoyi Wang; Xinya Jiang; Beisha Tang; Jiasheng Fang; Changqing Chen; Zhongliang Hu
Journal:  Acta Radiol       Date:  2009-03       Impact factor: 1.990

9.  Differentiation of primary central nervous system lymphomas and glioblastomas: comparisons of diagnostic performance of dynamic susceptibility contrast-enhanced perfusion MR imaging without and with contrast-leakage correction.

Authors:  C H Toh; K-C Wei; C-N Chang; S-H Ng; H-F Wong
Journal:  AJNR Am J Neuroradiol       Date:  2013-01-24       Impact factor: 3.825

10.  Assessment of vascular supply of hypervascular extra-axial brain tumors with 3T MR regional perfusion imaging.

Authors:  A Sasao; T Hirai; S Nishimura; H Fukuoka; R Murakami; M Kitajima; T Okuda; M Akter; M Morioka; S Yano; H Nakamura; K Makino; J-i Kuratsu; K Awai; Y Yamashita
Journal:  AJNR Am J Neuroradiol       Date:  2009-10-22       Impact factor: 3.825

View more
  2 in total

1.  Arterial spin-labeling is useful for the diagnosis of residual or recurrent meningiomas.

Authors:  Kazufumi Kikuchi; Akio Hiwatashi; Osamu Togao; Koji Yamashita; Ryotaro Kamei; Koji Yoshimoto; Koji Iihara; Satoshi O Suzuki; Toru Iwaki; Yuriko Suzuki; Hiroshi Honda
Journal:  Eur Radiol       Date:  2018-04-13       Impact factor: 5.315

2.  rCBV- and ADC-based Grading of Meningiomas With Glimpse Into Emerging Molecular Diagnostics.

Authors:  Seema Rohilla; Harender K Garg; Ishwar Singh; Rohtas K Yadav; Dhara B Dhaulakhandi
Journal:  Basic Clin Neurosci       Date:  2018-11-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.